Transfusion and Apheresis Science最新文献

{"title":"Mononuclear cell recruitment during extracorporeal photopheresis: Partial results of a phase 1/2 randomized clinical trial in multiple sclerosis","authors":"Yandy Marx Castillo-Aleman ,&nbsp;Carlos Agustin Villegas-Valverde ,&nbsp;Yendry Ventura-Carmenate ,&nbsp;Fatema Mohammed Al-Kaabi ,&nbsp;Shinnette Lumame ,&nbsp;Charisma Castelo ,&nbsp;Ruqqia Mir ,&nbsp;Lev Brylev ,&nbsp;Mutaz Atieh ,&nbsp;Muhammad Touseef Haider ,&nbsp;Antonio Alfonso Bencomo-Hernandez","doi":"10.1016/j.transci.2025.104095","DOIUrl":"10.1016/j.transci.2025.104095","url":null,"abstract":"<div><h3>Background</h3><div>Despite the routine clinical use of extracorporeal photopheresis (ECP) for the last decades, there has been no sufficient investigation on the intra-apheresis dynamics of mononuclear cells (MNCs).</div></div><div><h3>Objective</h3><div>This research aims to verify the \"intra-apheresis recruitment\" (IAR) of MNCs, which may be particularly useful in cases with low preapheresis MNC counts.</div></div><div><h3>Methods</h3><div>Prospective data of ECP procedures for patients with multiple sclerosis (MS) in the context of the PHOMS study (<span><span>NCT05168384</span><svg><path></path></svg></span>) were analyzed. ECPs were performed with the use of the Therakos® CellEx® Photopheresis System, and the recruitment factor (RF), collection efficiency 1 (CE₁), and fold enrichment (FE) for MNCs, lymphocytes, monocytes, and neutrophils were calculated at various intervals per the approved protocol.</div></div><div><h3>Results</h3><div>A total of 252 ECP procedures were performed on nine patients with MS, and data from 45 ECPs were analyzed for this study. IAR (RF ≥ 1) of MNCs, lymphocytes, and monocytes was observed in the 93.3 %, 95.5 %, and 88.8 % of the ECP procedures, respectively. CE₁ exceeded 100 % for these populations in 13.3 %, 11.1 %, and 24.4 % of ECPs, while FE ≥ 1 for MNCs and lymphocytes was found in all ECPs, and in 97.8 % of ECPs for monocytes. Additionally, RF correlated positively with CE₁ for MNCs (r = 0.40, p = 0.006) and lymphocytes (r = 0.43, p = 0.003), as well as with FE for monocytes (r = 0.39, p = 0.01) and lymphocytes (r = 0.48, p = 0.001), further improving collection quality.</div></div><div><h3>Conclusions</h3><div>Administering photopheresis with suboptimal MNC counts was plausible and did not worsen the anticipated cytopenias. Moreover, our findings revealed sustained IAR of MNCs in patients with MS who underwent ECP.</div></div>","PeriodicalId":49422,"journal":{"name":"Transfusion and Apheresis Science","volume":"64 2","pages":"Article 104095"},"PeriodicalIF":1.4,"publicationDate":"2025-02-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143388103","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Immunoglobulin use – Helpful treatment or panacea?","authors":"Cees Th. Smit Sibinga","doi":"10.1016/j.transci.2025.104091","DOIUrl":"10.1016/j.transci.2025.104091","url":null,"abstract":"","PeriodicalId":49422,"journal":{"name":"Transfusion and Apheresis Science","volume":"64 2","pages":"Article 104091"},"PeriodicalIF":1.4,"publicationDate":"2025-02-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143394343","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Colleagues from around the world have given generously of their time and expertise to produce The 2024 International Survey of Platelet Products and Practice and two related manuscripts in this issue of Transfusion and Apheresis Science","authors":"Kenneth E. Nollet,&nbsp;Hitoshi Ohto","doi":"10.1016/j.transci.2025.104085","DOIUrl":"10.1016/j.transci.2025.104085","url":null,"abstract":"","PeriodicalId":49422,"journal":{"name":"Transfusion and Apheresis Science","volume":"64 2","pages":"Article 104085"},"PeriodicalIF":1.4,"publicationDate":"2025-02-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143348949","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Adapting the Cohn 6th cold ethanol fractionation method for small plasma pools: An innovative platform for developing hyperimmunoglobulin products against antibiotic-resistant infections in resource-limited settings","authors":"Mikayel Ginovyan ,&nbsp;Gayane Kirakosyan","doi":"10.1016/j.transci.2025.104093","DOIUrl":"10.1016/j.transci.2025.104093","url":null,"abstract":"<div><div>The growing challenge of antimicrobial resistance (AMR) requires innovative strategies to combat multidrug-resistant infections. Vaccination is an effective approach, often considered a potential solution, however, its application against some of the most challenging multidrug-resistant bacteria, has been unsuccessful so far. In contrast, passive immunotherapy using high-titer specific antibodies can offer immediate solutions for infections where conventional antibiotics fail. This study describes the adaptation of the Cohn 6th cold ethanol fractionation method for small plasma pools, enabling the production of high-quality intravenous immunoglobulin (IVIG) products in resource-limited settings. Using small-scale plasma batches (12 L), the modified protocol achieved a yield of 4.5 ± 0.2 g/L IgG with &gt; 98 % purity, meeting European Pharmacopoeia requirements. Additional purification, viral safety, and filtration steps ensured sterility, low endotoxin levels, and robust viral inactivation. Safety evaluations confirmed sterility, absence of pyrogens, and stability over 24 months. This scalable methodology provides a practical platform for developing hyperimmunoglobulin products targeting AMR pathogens, particularly in resource-limited countries where large-scale fractionation infrastructure is unavailable and also not suitable. Our future efforts will focus on integrating this platform into combination therapies to enhance clinical outcomes in AMR infection management.</div></div>","PeriodicalId":49422,"journal":{"name":"Transfusion and Apheresis Science","volume":"64 2","pages":"Article 104093"},"PeriodicalIF":1.4,"publicationDate":"2025-02-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143286781","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Editorial commentary","authors":"Jerard Seghatchian","doi":"10.1016/j.transci.2025.104089","DOIUrl":"10.1016/j.transci.2025.104089","url":null,"abstract":"","PeriodicalId":49422,"journal":{"name":"Transfusion and Apheresis Science","volume":"64 2","pages":"Article 104089"},"PeriodicalIF":1.4,"publicationDate":"2025-02-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143349568","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Biographies of the guest editors for this issue's theme papers on current platelet transfusion practices around the world","authors":"","doi":"10.1016/j.transci.2025.104094","DOIUrl":"10.1016/j.transci.2025.104094","url":null,"abstract":"","PeriodicalId":49422,"journal":{"name":"Transfusion and Apheresis Science","volume":"64 2","pages":"Article 104094"},"PeriodicalIF":1.4,"publicationDate":"2025-02-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143372941","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Correlation between blood parameters in the early and later stages of pregnancy: A retrospective study","authors":"Nisreen Ibrahim ,&nbsp;Shatha H. Alziyadi ,&nbsp;Noorayisahbe Mohd Yaacob ,&nbsp;Ahlam AlGhamdi ,&nbsp;Mansour Alanazi ,&nbsp;Jaber Alfaifi ,&nbsp;Jawaher Bin J. Umah ,&nbsp;Mohamed Doheir ,&nbsp;Omaima A. Hamid ,&nbsp;Malik Alazzam","doi":"10.1016/j.transci.2025.104084","DOIUrl":"10.1016/j.transci.2025.104084","url":null,"abstract":"<div><h3>Objective</h3><div>Anemia is common in pregnant women and is associated with various maternal and fetal complications. However, the effect of fluctuations in hemoglobin levels during pregnancy on birth outcomes remains unclear. Therefore, we investigated the association between maternal hemoglobin levels at different stages of pregnancy and delivery outcomes.</div></div><div><h3>Methods</h3><div>This retrospective study included 215 women who gave birth between 2018 and 2023. Hemoglobin levels were measured at three time points during pregnancy: first trimester (approximately 12 weeks), second trimester (13–27 weeks), and third trimester (28–36 weeks). The primary outcomes were the associations between hemoglobin levels and birth weight, birth weight Z-score, placental ratio, and placental weight. Statistical analyses were conducted to control for maternal and fetal factors and to determine the correlations between hemoglobin levels and delivery outcomes.</div></div><div><h3>Results</h3><div>Hemoglobin levels in the first trimester were the best predictors of anemia in the third trimester (area under the curve (AUC), 0.63; sensitivity, 65 %; specificity, 65 %). Hemoglobin levels were inversely associated with birth weight, birth weight Z-score, placental ratio, and placental weight. The overall accuracy of predicting iron-deficiency anemia was high (sensitivity, 71 %; specificity, 76 %; AUC, 0.76). Significant associations were observed at p &lt; 0.001.</div></div><div><h3>Conclusions</h3><div>Fluctuations in hemoglobin levels during pregnancy were significantly associated with adverse birth outcomes. Monitoring and managing hemoglobin levels early in pregnancy can improve maternal and fetal health by reducing the risk of low birth weight and other complications. Further research is needed to explore the mechanisms underlying these associations and develop targeted interventions.</div></div>","PeriodicalId":49422,"journal":{"name":"Transfusion and Apheresis Science","volume":"64 2","pages":"Article 104084"},"PeriodicalIF":1.4,"publicationDate":"2025-02-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143388102","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Pathogen-reduction technology, good in more than one way for cellular blood components, is replacing irradiation","authors":"Willy Albert Flegel","doi":"10.1016/j.transci.2025.104088","DOIUrl":"10.1016/j.transci.2025.104088","url":null,"abstract":"<div><div>Clinical application of pathogen-reduction technology (PRT) is often restricted to platelet and non-cellular components, representing a minor fraction of the overall blood supply. The greatest benefit for patient safety may eventually derive from PRT in red cells, which is still unavailable for routine use. PRT is more effective to inactivate leukocytes than current irradiation, particularly pertinent for Japan with the only universal irradiation of cellular blood components. Elsewhere, only vulnerable patient cohorts are receiving irradiated cellular components. Blood components treated with approved PRT systems are exempt from irradiation if the patient requires irradiated components. Transfusion medicine has a strategic opportunity to develop and eventually utilize PRT for all cellular components, other than hematopoietic progenitor cell products. PRT would then enable leukocyte inactivation for 100 % of the blood supply, beneficial for transfusion safety in all patients.</div></div>","PeriodicalId":49422,"journal":{"name":"Transfusion and Apheresis Science","volume":"64 2","pages":"Article 104088"},"PeriodicalIF":1.4,"publicationDate":"2025-02-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143394342","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Update on the measurement of \"soluble angiotensin converting enzyme 2\" in plasma and its emerging significance as a novel biomarker of cardiovascular and kidney diseases: A concise commentary","authors":"Jean Amiral,&nbsp;Rémy Ferol","doi":"10.1016/j.transci.2025.104090","DOIUrl":"10.1016/j.transci.2025.104090","url":null,"abstract":"<div><div>Angiotensin Converting Enzyme 2 has emerged as a major cell-surface enzyme receptor for controlling the Renin-Angiotensin-Aldosterone-System. The SARS-Cov-2 pandemics has focused a major interest on that cell-surface receptor. It is the virus entry door for cell infection, and when inside it can replicate and lead to cell destruction. In some physio-pathological conditions, ADAM 17 and TMPSSR2 enzymes can cleave ACE2 on the cell surface and release its extra-cellular domain into the blood circulation. Measurement of this soluble protein then becomes possible, preferentially in plasma, but also in serum. Clinical studies have shown that Soluble ACE2 is an emerging biomarker for cardiovascular and kidney diseases and it could be of prognostic value for heart failure and kidney dysfunctions. In Covid-19 its diagnostic value is controversial, and the various studies lead to different conclusions. Many laboratory assays have been reported for the measurement of this biomarker. They concern enzymatic assays, aptamer methods, or immunoassays, either chemiluminescent or ELISA. Normal and pathological plasma concentrations reported with the various assays yet lack standardization and are very heterogenous. Recently introduced immunoassays tend to yield more compliant results despite variations due to the assay design and calibration, or the antibody targeted epitopes and reactivity. This article reports an ELISA designed with affinity purified rabbit polyclonal antibodies, obtained with recombinant ACE2 and calibrated with the recombinant protein in plasma. This assay has a global reactivity with the various ACE2 protein epitopes. Assay performance characteristics, and values measured in normal populations are presented. Availability of optimized ELISAs can contribute to a better harmonization of sACE2 measurements in plasma, and confirm its clinical significance as biomarker.</div></div>","PeriodicalId":49422,"journal":{"name":"Transfusion and Apheresis Science","volume":"64 2","pages":"Article 104090"},"PeriodicalIF":1.4,"publicationDate":"2025-02-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143349569","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Considerations on risk mitigating strategies for bacterial contamination of platelet concentrates – The Dutch perspective","authors":"Pieter F. van der Meer ,&nbsp;Vĕra M.J. Novotny ,&nbsp;Thomas L.R. Klei","doi":"10.1016/j.transci.2025.104087","DOIUrl":"10.1016/j.transci.2025.104087","url":null,"abstract":"<div><div>Due to their storage at room temperature, platelet concentrates are at risk for bacterial outgrowth if the unit is contaminated. Nowadays, various mitigation strategies are available, including bacterial screening and pathogen inactivation. Since pathogen inactivation technologies impact the clinical efficacy of the platelets, including but not limited to lower increments after transfusion and more significant bleeding, a balance needs to be struck between the safety and efficacy of platelet transfusions. In this Brief Review, we discuss the current situation in the Netherlands.</div></div>","PeriodicalId":49422,"journal":{"name":"Transfusion and Apheresis Science","volume":"64 2","pages":"Article 104087"},"PeriodicalIF":1.4,"publicationDate":"2025-02-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143376682","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}